CAG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Conagra Brands is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading just below resistance with mixed technicals, weak revenue growth, margin pressure, and broad analyst downgrades/target cuts. While earnings improved year over year and options sentiment is mildly bullish, the overall setup is more suitable for a cautious hold than an immediate buy. Since the user wants a direct answer and is unwilling to wait for a perfect entry, my clear view is: do not buy CAG now; wait for stronger confirmation.
Price closed at 14.34, just under pivot resistance at 14.103 with near-term resistance at 14.466 and 14.69. MACD histogram is positive and expanding, which supports short-term momentum, but RSI at 56.6 is neutral, not overbought. The bigger issue is the trend structure: SMA_200 > SMA_20 > SMA_5 is bearish, showing the stock is still in a longer-term downtrend despite recent stabilization. Overall technicals suggest a short-term bounce attempt inside a broader weak trend.
["Latest quarter showed net income up 37.7% YoY and EPS up 40% YoY.", "MACD is positive and expanding, suggesting improving short-term momentum.", "Options flow is mildly bullish with put/call ratios below 1.0.", "News flow includes sustainability and food safety updates that may support brand stability rather than create downside pressure."]
["Revenue fell 1.87% YoY in the latest quarter, showing weak top-line growth.", "Gross margin declined 6.12% YoY, pointing to profitability pressure.", "Analysts have recently lowered price targets and several ratings have moved to Neutral/Hold.", "Congress trading data shows 2 sales and 0 purchases, indicating cautious sentiment.", "Technical trend remains bearish on moving averages, with the stock still below long-term trend strength."]
In the latest reported quarter, Q3 2026, Conagra posted revenue of 2.788 billion, down 1.87% YoY, which shows sales are still slipping. On the positive side, net income rose 37.7% YoY to 199.8 million and EPS increased 40% YoY to 0.42, so earnings held up better than sales. The main concern is margin compression: gross margin fell to 23.63%, down 6.12% YoY, which suggests cost pressure remains a problem.
Recent analyst sentiment has turned more cautious. Morgan Stanley and Stifel both cut price targets to 15 and kept Equal Weight/Hold-type ratings, while BNP Paribas downgraded the stock to Neutral and UBS maintained Neutral. Barclays is still relatively constructive with an Overweight rating, but it also lowered its target. Overall, Wall Street’s view is mixed to negative: the pros see some volume improvement in key segments and valuation support, while the cons focus on muted volume growth, margin pressure, commodity cost risk, and limited upside.
